ARDX [NASD]
Ardelyx, Inc.
Index- P/E- EPS (ttm)-1.40 Insider Own1.90% Shs Outstand130.94M Perf Week13.41%
Market Cap93.78M Forward P/E- EPS next Y-0.38 Insider Trans-68.12% Shs Float98.48M Perf Month-16.74%
Income-153.10M PEG- EPS next Q-0.19 Inst Own29.90% Short Float11.72% Perf Quarter-10.90%
Sales4.00M P/S23.45 EPS this Y-44.20% Inst Trans-1.74% Short Ratio3.17 Perf Half Y-37.35%
Book/sh0.49 P/B1.34 EPS next Y29.10% ROA-93.50% Target Price4.83 Perf Year-90.37%
Cash/sh0.63 P/C1.05 EPS next 5Y30.00% ROE-177.10% 52W Range0.58 - 8.25 Perf YTD-40.20%
Dividend- P/FCF- EPS past 5Y11.50% ROI-134.30% 52W High-92.02% Beta1.89
Dividend %- Quick Ratio2.30 Sales past 5Y- Gross Margin97.90% 52W Low14.00% ATR0.08
Employees86 Current Ratio2.40 Sales Q/Q-92.40% Oper. Margin- RSI (14)38.94 Volatility8.89% 9.98%
OptionableYes Debt/Eq0.41 EPS Q/Q37.20% Profit Margin- Rel Volume0.45 Prev Close0.69
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume3.64M Price0.66
Recom2.00 SMA20-15.90% SMA50-27.89% SMA200-39.64% Volume1,650,569 Change-5.22%
May-06-22Downgrade Cantor Fitzgerald Overweight → Neutral $7 → $1
Dec-01-21Upgrade Ladenburg Thalmann Neutral → Buy $6
Oct-14-21Downgrade Ladenburg Thalmann Buy → Neutral
Jul-21-21Downgrade Jefferies Buy → Hold $11 → $2
Jul-20-21Downgrade Wedbush Outperform → Neutral $3
Jul-20-21Downgrade Piper Sandler Overweight → Neutral $14 → $4
Mar-23-21Initiated Wedbush Outperform $14
Jan-06-21Initiated Cantor Fitzgerald Overweight $14
Oct-20-20Resumed Citigroup Buy $13
Feb-18-20Resumed Jefferies Buy $11
Feb-12-20Initiated Citigroup Buy $13
Feb-10-20Initiated Cowen Outperform
Apr-08-19Initiated Piper Jaffray Overweight $15
Aug-24-18Initiated Jefferies Buy $7
Mar-19-18Resumed Leerink Partners Outperform $13
Nov-29-17Reiterated Citigroup Buy $16 → $17
Nov-22-17Reiterated Ladenburg Thalmann Buy $19 → $16
Oct-17-17Resumed Leerink Partners Outperform
Mar-31-16Initiated Ladenburg Thalmann Buy
Mar-09-16Initiated Cantor Fitzgerald Buy $19
May-17-22 04:01PM  
May-16-22 04:01PM  
May-05-22 05:35PM  
04:01PM  
May-02-22 04:01PM  
Apr-28-22 08:00AM  
Apr-25-22 04:53PM  
07:00AM  
Apr-12-22 04:26PM  
Apr-11-22 01:14PM  
07:00AM  
Apr-07-22 08:00AM  
Apr-04-22 08:00AM  
Mar-09-22 04:01PM  
Mar-02-22 06:55PM  
01:54PM  
Feb-28-22 05:55PM  
04:01PM  
Feb-24-22 06:00PM  
08:00AM  
Feb-22-22 08:00AM  
Feb-04-22 04:01PM  
Feb-02-22 01:38PM  
Jan-26-22 01:38PM  
Jan-12-22 11:21AM  
Dec-28-21 08:32AM  
Dec-10-21 09:00PM  
Dec-02-21 09:50AM  
Dec-01-21 11:44AM  
11:24AM  
10:59AM  
Nov-30-21 07:00AM  
Nov-24-21 11:30AM  
Nov-12-21 08:00AM  
Nov-11-21 04:05PM  
Nov-10-21 10:53AM  
Nov-05-21 08:00AM  
Nov-04-21 08:00AM  
Oct-29-21 08:00AM  
Oct-27-21 10:49AM  
Oct-13-21 05:00PM  
08:00AM  
Sep-30-21 06:27PM  
Sep-29-21 01:11PM  
Sep-28-21 12:22PM  
10:57AM  
09:20AM  
09:09AM  
07:50AM  
05:40AM  
Sep-27-21 09:15PM  
08:45PM  
12:10PM  
10:53AM  
10:00AM  
10:00AM  
08:30AM  
05:19AM  
Sep-26-21 03:15PM  
12:00PM  
Sep-24-21 05:00PM  
03:45PM  
12:20PM  
11:00AM  
11:00AM  
09:58AM  
09:45AM  
08:15AM  
Sep-23-21 08:51PM  
07:20PM  
11:35AM  
11:00AM  
09:15AM  
08:28AM  
05:40AM  
Sep-22-21 09:08PM  
06:35PM  
05:03PM  
04:17PM  
12:10PM  
08:00AM  
Sep-21-21 03:40PM  
02:22PM  
09:00AM  
08:20AM  
Sep-20-21 07:15PM  
06:40PM  
10:40AM  
10:07AM  
09:20AM  
08:20AM  
06:21AM  
Sep-19-21 10:21AM  
Sep-18-21 10:02AM  
Sep-17-21 07:15PM  
06:00PM  
05:39PM  
11:45AM  
11:00AM  
09:15AM  
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rosenbaum David P.Chief Development OfficerFeb 22Sale0.67601403105,026Feb 25 04:55 PM
Rosenbaum David P.Chief Development OfficerFeb 22Sale0.671,7521,174349,409Feb 25 04:55 PM
RAAB MICHAELPresident & CEOFeb 22Sale0.676,2294,173775,574Feb 25 04:56 PM
Blanks RobertSee RemarksFeb 22Sale0.671,7521,174399,116Feb 25 04:57 PM
Rodriguez SusanChief Commercial OfficerFeb 22Sale0.673,4002,278333,938Feb 25 04:54 PM
BASKETT FOREST10% OwnerDec 15Sale1.141,211,3521,384,6962,258,850Dec 27 05:40 PM
SANDELL SCOTT D10% OwnerDec 15Sale1.141,211,3521,384,6962,258,850Dec 27 05:40 PM
SANDELL SCOTT D10% OwnerDec 14Sale1.241,000,7351,245,0142,285,682Dec 27 05:40 PM
BASKETT FOREST10% OwnerDec 14Sale1.241,000,7351,245,0142,285,682Dec 27 05:40 PM
BASKETT FOREST10% OwnerDec 09Sale1.51669,4831,012,8612,476,756Dec 27 05:40 PM
SANDELL SCOTT D10% OwnerDec 09Sale1.51669,4831,012,8612,476,756Dec 27 05:40 PM
GRAMMER ELIZABETH ASee RemarksNov 22Sale0.99537533275,958Nov 24 04:05 PM
Rodriguez SusanChief Commercial OfficerNov 22Sale0.99643638197,030Nov 24 04:08 PM
Rosenbaum David P.Chief Development OfficerNov 22Sale0.9918418290,627Nov 24 04:08 PM
Rosenbaum David P.Chief Development OfficerNov 22Sale0.99643638311,161Nov 24 04:08 PM
Blanks RobertSee RemarksNov 22Sale0.99643638360,868Nov 24 04:05 PM
Jacobs Jeffrey WChief Scientific OfficerNov 22Sale0.985,7545,629119,483Nov 24 04:06 PM
RAAB MICHAELPresident & CEONov 22Sale0.992,6072,586631,803Nov 24 04:06 PM
Renz Justin AChief Financial OfficerNov 22Sale0.99643638293,687Nov 24 04:07 PM
Jacobs Jeffrey WChief Scientific OfficerNov 15Sale1.135,0005,650125,237Nov 16 05:54 PM
GRAMMER ELIZABETH ASee RemarksNov 12Sale1.1277,43287,111276,495Nov 12 07:09 PM
Jacobs Jeffrey WChief Scientific OfficerNov 08Sale1.182,1662,556130,237Nov 10 05:17 PM
Rosenbaum David P.Chief Development OfficerAug 20Sale1.3217623226,574Aug 24 06:08 PM
Rosenbaum David P.Chief Development OfficerAug 20Sale1.32631833158,804Aug 24 06:08 PM
RAAB MICHAELPresident & CEOAug 20Sale1.322,5733,396329,730Aug 24 06:06 PM
Renz Justin AChief Financial OfficerAug 20Sale1.3263183340,047Aug 24 06:07 PM
Rodriguez SusanChief Commercial OfficerAug 20Sale1.3263083244,673Aug 24 06:07 PM
Jacobs Jeffrey WChief Scientific OfficerAug 20Sale1.32741978127,697Aug 24 06:06 PM
Blanks RobertSee RemarksAug 20Sale1.32631833106,323Aug 24 06:05 PM
GRAMMER ELIZABETH ASee RemarksAug 20Sale1.32526694102,386Aug 24 06:05 PM
RAAB MICHAELPresident & CEOAug 03Option Exercise0.54267,892144,662482,646Aug 05 05:01 PM
Jacobs Jeffrey WChief Scientific OfficerAug 03Option Exercise0.5410,0005,400134,051Aug 05 05:00 PM
Jacobs Jeffrey WChief Scientific OfficerJun 15Option Exercise0.547,5004,050131,551Jun 17 04:32 PM
Jacobs Jeffrey WChief Scientific OfficerJun 15Sale7.297,50054,658124,051Jun 17 04:32 PM
Rosenbaum David P.Chief Development OfficerMay 28Sale7.223,06222,09826,750Jun 02 07:23 PM
Rosenbaum David P.Chief Development OfficerMay 20Sale7.091571,11329,812May 21 04:49 PM
Rosenbaum David P.Chief Development OfficerMay 20Sale7.096124,338159,435May 21 04:49 PM
Rodriguez SusanChief Commercial OfficerMay 20Sale7.096114,33145,303May 21 04:49 PM
RAAB MICHAELPresident & CEOMay 20Sale7.092,53417,960214,754May 21 04:47 PM
Renz Justin AChief Financial OfficerMay 20Sale7.096124,33840,678May 21 04:48 PM
Blanks RobertSee RemarksMay 20Sale7.096124,338106,954May 21 04:46 PM
GRAMMER ELIZABETH ASee RemarksMay 20Sale7.095083,601102,912May 21 04:46 PM
Jacobs Jeffrey WChief Scientific OfficerMay 20Sale7.097215,110124,051May 21 04:47 PM